New Study Examines Time-Related Relationship Between Diabetes and Cancer

Article

Patients with diabetes are more likely to get a cancer diagnosis ten years prior or three months after their diabetes diagnosis, according to a recent study.

Type 2 diabetes is associated with an increased likelihood of a cancer diagnosis, according to the recent findings of a large Canadian study.

The strongest correlation was 10 years prior and three months after a diabetes diagnosis, according to the study, which was conducted by Iliana Lega and her colleagues at the University of Toronto.

People with diabetes were more likely to have been diagnosed with a first cancer within the decade before diabetes diagnosis, when compared with those without diabetes. Once diagnosed with diabetes, there is a spike in cancer occurrence in the first three months, as those with diabetes had a 62 percent greater chance of being diagnosed with cancer than those without diabetes.

“This may, in part, be explained by increased health care visits and screening tests following a diagnosis of diabetes,” Lega said in a statement.

After the three-month mark, the difference in cancer statistics between those with diabetes and those without leveled off.

But while detection bias may play a role in the number of cancer diagnoses within the first few months of a diabetes diagnosis, the reason for the higher prevalence (23 percent) of cancer a decade prior likely has more to do with the risk factors leading up to diabetes, independent of seeing a doctor.

“This observation may be due to shared metabolic risk factors for diabetes and cancer that are present during the prediabetes period, such as insulin resistance and hyperinsulinemia,” the study’s authors wrote. “These metabolic alterations may precede a clinical diagnosis of diabetes by up to 10 years.”

The study looked at 516,219 patients with diabetes, and matched them with a control group of 516,219 non-diabetics. All patients were 30 years of age or older, leading the study to reflect cancer risk for type 2 diabetes, since type 1 diabetes is rare in this age group, Lega said in an interview with CURE.

Diabetes was associated with a “significantly increased risk” of pancreatic, endometrial, liver and thyroid cancers in both time periods studied. There was a jump in colorectal and bladder cancers within the first three months of a diabetes diagnosis, but it then leveled off.

As diabetes rates continue to grow in many countries, including the United States, the authors of the study emphasized the importance of intervention and prevention.

“We have excellent evidence that diabetes can be reversed with physical activity and lifestyle interventions in high-risk individuals,” the study’s authors wrote. “Such interventions are urgently needed both on an individual and population level, not only to reduce the risk of diabetes and vascular complications, but also to potentially reduce the burden of cancer in this population.”

Further, Lega mentioned that increased screening could improve outcomes for people with diabetes who may potentially have cancer as well.

“Our findings suggest that people with diabetes, and even those at risk for diabetes, may have a higher risk of cancer and therefore may benefit from enhanced cancer screening and prevention programs,” she said. “However, more research is needed to assess how to best implement such targeted programs in this high-risk population.”

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content